GlassScriptPhysician profile
Rhiannon Soukup
NPI 1366140071
$5,010.29
in general payments reported to CMS, 2019-2025
23 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,612 · 2024: $2,017 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,010.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $737.87 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $698.03 | 2023-2025 | |
| Alkermes, INC. | $655.16 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $567.36 | 2023-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $436.63 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $321.87 | 2023-2025 | Spravato |
| Lundbeck LLC | $296.50 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $240.25 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $228.82 | 2023-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $157.92 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $107.95 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $102.70 | 2023-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $97.51 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $75.29 | 2023-2024 | Trintellix |
| Avion Pharmaceuticals | $66.92 | 2023-2024 | Methylphenidate Hydrochloride |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $63.06 | 2023-2024 | Aplenzin |
| Noven Therapeutics, LLC | $38.09 | 2023-2024 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $35.09 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $28.95 | 2023-2024 | Jornay Pm |
| Acadia Pharmaceuticals INC | $25.69 | 2023 | Nuplazid |
| Neos Therapeutics, LP | $16.57 | 2023 | Adzenys Xr-Odt |
| Neuronetics, INC. | $11.06 | 2023 | Neurostar Tms Therapy System |
| Brainsway USA INC | $1.00 | 2024 | Brainsway Deep Tms System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhiannon Soukup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.